YBYoung Bull
Menu
StocksPortfolioThemesMacroAI NewsResearchAbout
COMPANY WORKBOOK · INCY

Incyte Corporation

Healthcare & Life Sciences · Biotechnology

$119.65+1.39%
64/100
Overall
MARKET CAP24.39B
FORWARD P/E13.85
PEG RATION/A
REVENUE GROWTH14.0%
OPERATING MARGIN33.7%
52W RANGE$90.30 – $129.93
ChartScoreRelative StrengthFinancialsEarningsThesisFiles
INTERACTIVE PRICE CHART

Trend and moving averages

RELATIVE PERFORMANCE

INCY versus SPY and SMH

Indexed to 100
LIVE MODEL SCORE

Cross-sectional ranking

Momentum69
Technicals75
Fundamentals58
Thematic Fit55

Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.

YOUNG BULL THESIS

Healthcare & Life Sciences

This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.

MODEL READ

Overall score: 64.4. Last ranked 2026-11-07.

QUARTERLY FUNDAMENTALS

Revenue and earnings power

TRAILING P/E61.05
PRICE / SALES4.06
EV / EBITDA10.11
BOOK VALUEN/A
GROSS MARGIN56.0%
PROFIT MARGIN6.7%
RETURN ON EQUITY7.8%
FREE CASH FLOW1.29B
EARNINGS HISTORY

Beat, miss and estimate trend

2026-09-30EPS -3.79Estimate -4.2711.2412% surprise
2026-06-30EPS 2.8Estimate 1.7659.0909% surprise
2026-03-31EPS 1.81Estimate 1.3435.0746% surprise
2025-12-31EPS 1.8Estimate 1.92-6.25% surprise
2025-09-30EPS 2.26Estimate 1.6437.8049% surprise
2025-06-30EPS 1.57Estimate 1.476.8027% surprise
2025-03-31EPS 1.16Estimate 1.0312.6214% surprise
2024-12-31EPS 1.43Estimate 1.55-7.7419% surprise
COMPANY SNAPSHOT

What it does

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

PRIMARY SOURCES

Files and filings

SEC FILINGS10-K, 10-Q, 8-K, proxy and ownership filingsMARKET PROFILEYahoo Finance profile and market dataINVESTOR WEBSITECompany investor materials and presentations